The initial treatment of Parkinson's disease should begin with levodopa
Identifieur interne : 002659 ( Main/Corpus ); précédent : 002658; suivant : 002660The initial treatment of Parkinson's disease should begin with levodopa
Auteurs : William J. WeinerSource :
- Movement Disorders [ 0885-3185 ] ; 1999-09.
English descriptors
- KwdEn :
Abstract
For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.
Url:
DOI: 10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q
Links to Exploration step
ISTEX:42D0059395A046E21B2586D694C8D0DB5F953E86Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><mods:affiliation>Department of Neurology, University of Miami School of Medicine, Miami, Florida, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:42D0059395A046E21B2586D694C8D0DB5F953E86</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</idno><idno type="url">https://api.istex.fr/document/42D0059395A046E21B2586D694C8D0DB5F953E86/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002659</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><mods:affiliation>Department of Neurology, University of Miami School of Medicine, Miami, Florida, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-09">1999-09</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="716">716</biblScope><biblScope unit="page" to="724">724</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">42D0059395A046E21B2586D694C8D0DB5F953E86</idno><idno type="DOI">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</idno><idno type="ArticleID">MDS1002</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine receptor agonists</term><term>Levodopa</term><term>Levodopa‐sparing strategies</term><term>Parkinson's disease</term><term>Toxicity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>William J. Weiner MD</name><affiliations><json:string>Department of Neurology, University of Miami School of Medicine, Miami, Florida, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine receptor agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Toxicity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Levodopa‐sparing strategies</value></json:item></subject><articleId><json:string>MDS1002</json:string></articleId><language><json:string>eng</json:string></language><abstract>For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.</abstract><qualityIndicators><score>6.104</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>686</abstractCharCount><pdfWordCount>5713</pdfWordCount><pdfCharCount>36735</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>92</abstractWordCount></qualityIndicators><title>The initial treatment of Parkinson's disease should begin with levodopa</title><genre><json:string>other</json:string></genre><host><volume>14</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>9</total><last>724</last><first>716</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Controversy</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><doi><json:string>10.1002/1531-8257(199909)14:5>716::AID-MDS1002>3.0.CO;2-Q</json:string></doi><id>42D0059395A046E21B2586D694C8D0DB5F953E86</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/42D0059395A046E21B2586D694C8D0DB5F953E86/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/42D0059395A046E21B2586D694C8D0DB5F953E86/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/42D0059395A046E21B2586D694C8D0DB5F953E86/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>WILEY</p></availability><date>1999</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title><author><persName><forename type="first">William J.</forename><surname>Weiner</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, University of Miami School of Medicine, 1501 NW 9th Ave., Miami, FL 33136, U.S.A.</p></note><affiliation>Department of Neurology, University of Miami School of Medicine, Miami, Florida, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-09"></date><biblScope unit="volume">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="716">716</biblScope><biblScope unit="page" to="724">724</biblScope></imprint></monogr><idno type="istex">42D0059395A046E21B2586D694C8D0DB5F953E86</idno><idno type="DOI">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</idno><idno type="ArticleID">MDS1002</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1999</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>Levodopa</term></item><item><term>Dopamine receptor agonists</term></item><item><term>Toxicity</term></item><item><term>Levodopa‐sparing strategies</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Controversy</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-05-06">Received</change><change when="1999-06-01">Registration</change><change when="1999-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/42D0059395A046E21B2586D694C8D0DB5F953E86/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/1531-8257(199909)14:5<>1.0.CO;2-4</doi><numberingGroup><numbering type="journalVolume" number="14">14</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="1999-09">September 1999</coverDate></publicationMeta><publicationMeta level="unit" type="miscellaneous" position="2" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</doi><idGroup><id type="unit" value="MDS1002"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Controversy</title><title type="tocHeading1">Controversies</title></titleGroup><copyright ownership="thirdParty">Copyright © 1999 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1999-05-06"></event><event type="manuscriptAccepted" date="1999-06-01"></event><event type="firstOnline" date="2001-01-16"></event><event type="publishedOnlineFinalForm" date="2001-01-16"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-04"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-01"></event></eventGroup><numberingGroup><numbering type="pageFirst">716</numbering><numbering type="pageLast">724</numbering></numberingGroup><correspondenceTo>Department of Neurology, University of Miami School of Medicine, 1501 NW 9th Ave., Miami, FL 33136, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1002.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="60"></count><count type="wordTotal" number="5569"></count></countGroup><titleGroup><title type="main" xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title><title type="short" xml:lang="en">Treatment of Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>William J.</givenNames><familyName>Weiner</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Miami School of Medicine, Miami, Florida, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">Levodopa</keyword><keyword xml:id="kwd3">Dopamine receptor agonists</keyword><keyword xml:id="kwd4">Toxicity</keyword><keyword xml:id="kwd5">Levodopa‐sparing strategies</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The initial treatment of Parkinson's disease should begin with levodopa</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Treatment of Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The initial treatment of Parkinson's disease should begin with levodopa</title></titleInfo><name type="personal"><namePart type="given">William J.</namePart><namePart type="family">Weiner</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Miami School of Medicine, Miami, Florida, U.S.A.</affiliation><description>Correspondence: Department of Neurology, University of Miami School of Medicine, 1501 NW 9th Ave., Miami, FL 33136, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="other" displayLabel="miscellaneous"></genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">1999-09</dateIssued><dateCaptured encoding="w3cdtf">1999-05-06</dateCaptured><dateValid encoding="w3cdtf">1999-06-01</dateValid><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="references">60</extent><extent unit="words">5569</extent></physicalDescription><abstract lang="en">For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>Levodopa</topic><topic>Dopamine receptor agonists</topic><topic>Toxicity</topic><topic>Levodopa‐sparing strategies</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Controversy</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>716</start><end>724</end><total>9</total></extent></part></relatedItem><identifier type="istex">42D0059395A046E21B2586D694C8D0DB5F953E86</identifier><identifier type="DOI">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</identifier><identifier type="ArticleID">MDS1002</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1999 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Inc.</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002659 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002659 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:42D0059395A046E21B2586D694C8D0DB5F953E86
|texte= The initial treatment of Parkinson's disease should begin with levodopa
}}
| This area was generated with Dilib version V0.6.23. |  |